Evidence map›Paper›PMID 32751556›Full record

ReviewInternational journal of molecular sciences2020

Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma.

Stefano Burgio, Leila Noori, Antonella Marino Gammazza, Claudia Campanella, Mariantonia Logozzi, Stefano Fais, Fabio Bucchieri, Francesco Cappello, Celeste Caruso Bavisotto

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Review
  3. 80 years of extracellular vesicles: from discovery to clinical translation.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  4. Article
  5. Article
  6. Nanocarriers for cutting-edge cancer immunotherapies.Journal of translational medicine · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stefano BurgioDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Human Anatomy, University of Palermo, 90127 Palermo, Italy.ORCID 0000-0002-9497-5612
Leila NooriDepartment of Anatomy, School of Medicine, Tehran University of Medical Science, Tehran 141 765 3911, Iran.
Antonella Marino GammazzaDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Human Anatomy, University of Palermo, 90127 Palermo, Italy.ORCID 0000-0002-1683-3803
Claudia CampanellaDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Human Anatomy, University of Palermo, 90127 Palermo, Italy.
Mariantonia LogozziDepartment of Oncology and Molecular Medicine, National Institute of Health, 00161 Rome, Italy.
Stefano FaisDepartment of Oncology and Molecular Medicine, National Institute of Health, 00161 Rome, Italy.
Fabio BucchieriDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Human Anatomy, University of Palermo, 90127 Palermo, Italy.
Francesco CappelloDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Human Anatomy, University of Palermo, 90127 Palermo, Italy.
Celeste Caruso BavisottoDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Human Anatomy, University of Palermo, 90127 Palermo, Italy.ORCID 0000-0001-8260-8471

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research for the most selective drug delivery to tumors represents a fascinating key target in science. Alongside the artificial delivery systems identified in the last decades (e.g., liposomes), a family of natural extracellular vesicles (EVs) has gained increasing focus for their potential use in delivering anticancer compounds. EVs are released by all cell types to mediate cell-to-cell communication both at the paracrine and the systemic levels, suggesting a role for them as an ideal nano-delivery system. Malignant pleural mesothelioma (MPM) stands out among currently untreatable tumors, also due to the difficulties in achieving an early diagnosis. Thus, early diagnosis and treatment of MPM are both unmet clinical needs. This review looks at indirect and direct evidence that EVs may represent both a new tool for allowing an early diagnosis of MPM and a potential new delivery system for more efficient therapeutic strategies. Since MPM is a relatively rare malignant tumor and preclinical MPM models developed to date are very few and not reliable, this review will report data obtained in other tumor types, suggesting the potential use of EVs in mesothelioma patients as well.

Indexed as

Extracellular VesiclesAntineoplastic AgentsDrug CarriersHumansMesothelioma, MalignantAntineoplastic AgentsDrug Carriersdrug delivery systemsexosomesextracellular vesiclesmalignant pleural mesothelioma

Identifiers

PMID32751556
PMCPMC7432055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.